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Abstract: Malignant melanoma is a disease with high mortality rate caused by rapid metastasis. Cell motility is physically and 
biochemically restricted by cadherin-mediated cell interactions and signalling pathways, and alterations in cadherin expression strongly 
correlate with E to N-cadherin switch as well as the metastasis and progression of tumours. Contrary to E-cadherin, N-cadherin plays an 
important role in stimulating processes of cell division, migration, differentiation and death.  
In this study we investigated the role of N-cadherin in proliferation and AKT, ERK, beta-catenin signalling pathway in human melanoma 
cells: WM793(VGP), WM115(VGP) from the primary tumor site, as well as Lu1205(lung) and WM266-4(skin) from metastatic sites.  
N-cadherin, pAKT(S473), -catenin, pERK1/2(T202/Y204), cyclin D1, cyclin D3, cyclin-dependent kinases CDK4, CDK6, and p15, 
p16, p21, p27 inhibitors expression was determined by western blot analysis. The study on proliferation of cells was performed with the 
use of BrdU incorporation and crystal violet staining assays.  
Knock-out of N-cadherin gene expression by siRNA process reduced the expression of: pAKT(S473), pERK1/2(T202/Y204), beta-
catenin, cyclin D1, cyclin D3 , cyclin-dependent kinases CDK4, CDK6 while increasing expression of cell cycle inhibitors p21 and p27, 
and significantly decreased cell proliferation (50-70%). The collected data indicate that N-cadherin mediates the effect of cell cycle in G1 
phase by AKT, -catenin, and ERK signalling pathway.  
These results suggest that increased expression of N-cadherin significantly contributes to the increased invasive potential of melanoma 
cells. Silencing of N-cadherin arrests cell growth at G1 phase and inhibits the entry into S-phase which is of great importance as to its 
possible future use in cancer treatment. 
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INTRODUCTION 
Malignant melanoma is the most aggressive, therapy resistant 
and deadly form of skin cancer. It arises from malignant 
transformation of melanocytes, the pigmented skin cells. During the 
process of malignant transformation the nascent melanoma cells 
acquire the ability to proliferate indefinitely and escape from their 
local microenvironment. Microenvironmental escape is mediated 
through altered expression of cell-cell, cell-matrix adhesion 
proteins, among others. 
 Cadherins are transmembrane glycoproteins that provide strong 
intercellular adhesion in Ca
2+
 dependent manner. Classic cadherins 
are a transmembrane component of cellular junctions. They are 
composed of three segments: large extracellular domain, which 
mediates homophilic type cell adhesion, a transmembrane domain, 
and a highly conserved cytoplasmic domain that interacts with 
catenins to link cadherins to the actin cytoskeleton. Cadherins play 
a major role in epithelial cell-cell adhesion [1-2].  
Expression of N-cadherin has been reported in a variety of 
normal tissues including neuronal, endothelial and muscle cells and 
subpopulation of early haematopoietic progenitor cells [3]. In 
embryogenesis N-cadherin is the key molecule during gastrulation 
and neural crest development. It also regulates cell-surface adhesion 
through homotypic adhesion with the same cadherin species [3].  
Normally cultured human melanocytes express both E-cadherin 
and P-cadherin. E-cadherin is primarily responsible for adhesion of 
melanocytes to keratinocytes [4-6]. Melanocytes embedded in the 
epidermis among
 
the basal layer interact with keratinocytes through 
E-cadherin, which in effect regulates their growth. 
N-cadherin heavily glycosylated protein [7-8] is another classic 
cadherin expressed in human skin
 
by dermal fibroblasts and 
vascular endothelial cells, but not
 
by keratinocytes or melanocytes.  
Malignant transformation of melanocytes is frequently 
accompanied by loss of E-cadherin expression, and induction of  
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expression of mesenchymal molecules like N-cadherin. Normal 
melanocytes and the surrounding keratinocytes express E-cadherin 
to stable tissue assembly [9]. E-cadherin functions as an invasion 
suppressor and is down-regulated in most cancer, while N-cadherin 
is frequently up-regulated. H-cadherin and P-cadherin, just as E-
cadherin, reduce melanoma cell growth and invasion, but their 
expression decreases or disappears in malignant melanoma [10-11]. 
Recent literature data [12] suggest that during malignant 
transformation the extent of tumor cell invasion N-cadherin 
undergoes proteolytic processing altered, as a result of which an 
abundant amount of nonadhesive precursor N-cadherin (pro-N-
cadherin) is formed at the cell surface, although total N-cadherin 
levels remain constant. Pro-N-cadherin promotes cell migration and 
invasion in vitro. 
Expression of N-cadherin in epithelial cells induces changes in 
morphology of a fibroblastic phenotype, rendering the cells more 
motile and invasive.  
N-cadherin becomes more prevalent as tumours become more 
malignant and aggressive. N-cadherin expressed in melanoma cells 
not only mediates cell-cell interactions between adjacent cancer 
cells and stromal fibroblasts, as well as endothelial cells, but also 
promotes survival and migration of melanoma cells [2]. It is 
expressed by several human fetal tissues and re-expressed by the 
corresponding neoplasm, thus contributing to melanoma invasive 
phenotype [7, 4]. 
N-cadherin role in cell differentiation, transformation, and 
invasion has also been documented [13-16] with some of these 
functions, most probably depending upon the activation of 
intracellular signal transduction cascades [17-19]. However, the 
mechanism by which N-cadherin regulates entry into the cell cycle 
has not been fully elucidated.  
The key to successful cancer treatment is learning signalling 
hubs in the network-associated melanoma cells with proliferation 
and survival. Many attempts have been made to assess the
 
rate of 
tumor proliferation using various biological markers,
 
including 
mitotic rate, cyclins, and cyclin-dependent
 
kinase inhibitors such as 
p15, p16, p21 and p27.
 
Entry into the S-phase of cell cycle, critical 
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for future cell division, is regulated at the G1 restriction checkpoint, 
a process that becomes deregulated in cancer cells. Progression 
through the G1 into S-phase of the cell cycle is driven by cyclin 
dependent kinases (CDK) 4 and 6 which interact with cyclin D1and 
D3, as well as by CDK2 which interacts with cyclins A/E [20].  
In this study, we examined if and how N-cadherin might 
regulate melanoma cell proliferation by the control of cell cycle at 
G1 point. We studied the affect of N-cadherin using its siRNA-
mediated knock-down to levels of pAkt, ERK1/2, -catenin, cell 
cycle protein and proliferation.  
MATERIALS AND METHODS 
Cell Culture 
Human melanoma cell lines WM793 (VGP) -Lu1205 
(metastatic, lung) and WM115 (VGP) – WM266-4 (metastatic, 
skin) were cultured in RPMI-1640 medium supplemented with 10% 
fetal bovine serum and penicillin/streptomycin. Cells were treated 
with PI3K inhibitor – LY294002 (Cell Signalling TM) in 20μM 
concentration for 24h and ERK1/2 inhibitor - U0126 (Cell 
Signalling TM) in 10 μM concentration for 2h. Cells were obtained 
from the ESTDAB Melanoma Cell Bank (Tubingen, Germany). 
siRNA 
Two 21bp double-stranded siRNA CDH2 molecules 
specifically targeting for the N-cadherin: siRNA CDH2#1 created 
by in vitro transcription (Silencer TM siRNA Construction Kit 
(Ambion) and commercially available siRNA CDH2#2 (Ambion 
ID# S27773). Small interfering
 
RNA (siRNA) against the CDH2#1 
target sequence 5’-AAAGTGGCAAGTGGCAGTAAA-3’
 
(nucleotides 798-818; NM001792) was used. Effect of RNA 
interference on expression of CDH2 mRNA and protein was 
determined by reverse transcription-PCR (RT-PCR) and Western 
immunoblotting respectively. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as an internal control to 
monitor efficiency of RT-PCR.  
siRNA Transfection 
Melanoma cells were grown until 60% confluence and then 
transfected using Oligofectamine reagent (Invitrogen) according to 
the manufacturer’s protocol with two different, 21bp double-
stranded siRNA molecules specifically targeting for the N-cadherin: 
siRNA CDH2 - in vitro transcription (SilencerTM siRNA 
Construction Kit (Ambion)) and commercially available (Ambion 
ID#S27773) or a control nonsilencing sequence (Ambion). 
WM793, WM115, WM266-4 cells were transfected with 50 nM 
and Lu1205 cells with 100 nM siRNA. Medium was replaced 24h 
later with a fresh one and cells were grown for an additional 24h to 
48h period (48h or 72h post-tansfection) prior to further analysis. 
Gel Electrophoresis 
Gels were prepared in the presence of SDS in reducing 
conditions. Cell lysates containing equal amounts of protein were 
loaded per well and separated with the use 4.5% stacking and 10% 
(or 12%) separation gel in a 4h run.  
Western Blotting 
Proteins were transferred onto PVDF membrane overnight 
using a Trans-Blot Electrophoretic Transfer Cell (Bio-Rad) at 150 
mA in 25mM Tris, 192mM glycine, 20% methanol buffer at pH 
8.4. Antibodies used for probing Western blots were: anti-N-
cadherin, pERK1/2 (T202/Y204), ERK, -catenin (all Transduction 
Laboratories, BD), phospho--catenin (S33/37/T41), phospho--
catenin (S552), phospho--catenin (S675), AKT, phospho-AKT 
(S473), p15, p16, p21, p27, cyclin D1, cyclin D3, CDK4 kinase, 
CDK6 kinase, phospho- GSK-3 (S9), phospho-GSK-3 (Y216) 
(all Cell Signalling Technology), and -actin (Sigma). Bands were 
visualized using alkaline phosphate coupled with secondary anti-
mouse or anti-rabbit antibody (Sigma). Finally, immunoreactions 
were visualized by NBT/BCIP staining (Roche).  
Cell Proliferation Assay  
The proliferation of cells was assessed with the BrdU ELISA 
and crystal staining violet tests. The cells were plated at density 
5x103 cell/well for WM793 or WM115, and 3x10
3 
for Lu1205 or 
WM266-4 in 96 well plates. The cells were transfected with N-
cadherin siRNA and after a period of 24h medium was replaced 
with a fresh one. Proliferation assays were performed with 
conventional methods BrdU ELISA test (Roche) according to the 
manufacturer’s protocol. For the crystal violet test, cells were 
cultured for 48h or 72h at 37
o
 C, afterwards medium was removed 
and cells were washed with PBS. Thereupon, cells were fixed with 
200l 96% ethanol for 15 min, stained with 0.5% crystal violet, 
washed with water and air dried. After subsequent 30 min 
incubation of cells with elution solution (1:1 0.1 M Na
+
 citrate, pH 
4.2 to 100% ethanol 200 l per well), samples were measured at 
540 nm on a plate reader (BIO-TEK).  
Cytotoxicity Assay 
The cytotoxicity of N-cadherin siRNA (100 nM), PI3K 
inhibitor – LY294002 (20μM) ERK1/2 inhibitor - U0126 (10 μM) 
was assayed by determination of activity of lactate dehydrogenase 
(LDH) released by treated cells to medium (Cytotoxicity Detection 
Kit LDH, Roche, Germany). N-cadherin siRNA, LY294002 and 
U0126 inhibitor, showed no cytotoxicity effect in the course of 72h 
treatment of all melanoma cells as LDH activity in examined media 
never exceeded 3% of total LDH activity. 
Statistics 
Cell proliferation data were calculated from mean values of 
replicate experiments as indicated, using the Student’s t-test. 
Results were considered significant at p< 0.05. 
Densitometry Analysis 
Densitometry analysis of N-cadherin bound expression at the 
protein and mRNA level was performed on volume (sum of 
intensities bound) using UVIMAP V.99.03 software (UVItec St 
John’s Innovation Centr Cowley Road Cambridge CB4 OWS- 
England). 
RESULTS 
N-Cadherin Silencing by siRNA 
Melanoma cell lines: WM793, WM115 from VGP and Lu1205, 
and WM266-4 metastatic all express N-cadherin, but no E- and P-
cadherin, as was established on both on mRNA and protein levels. 
The gain of N-cadherin expression in melanoma has proved to be 
important in terms of its effect on cell migration, invasion, 
proliferation and survival. Two sequences of siRNA molecules 
specifically targeting for the N-cadherin: siRNACDH2#1designed 
by in vitro transcription (Silencer TM siRNA Construction Kit 
(Ambion)) and (ID#S27773) siRNACDH2#2 designed 
commercially efficiently reduced N-cadherin expressions (Fig. 1). 
The results of densitometry comparison of N-cadherin expression at 
the protein and mRNA level after knock-down of N-cadherin are 
presented in Table 1. 
Re-expression of E-cadherin on mRNA or protein level upon 
silencing of N-cadherin was not observed. 
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Fig. (1). N-cadherin silencing by siRNA. Effects of RNA interference on (A) protein level, western immunoblotting and (B) expression of mRNA were 
determined by reverse transcription-PCR (RT-PCR) 48h after transfection.  
 
Table 1. The Densitometry Analysis of N-Cadherin Expression at the Protein and mRNA Level After Knock-Down of N-Cadherin 
 
 Volume –intensities of bound/ percent of control 
Cell line Lu1205 WM793 WM115 WM266-4 
Protein level 
control 13060 (100%) 16935 (100%) 13452 (100%) 10794 (100%) 
siRNACDH2#2 6143 (47%) 2542 (15%) 5014 (37) 8137 (75%) 
siRNA CDH2#1 917 (7%) 1774 (10%) 679 (5%) 929 (8,6%) 
mRNA level 
control 28203 (100%) 27033 (100%) 29012 (100%) 31396 (100%) 
siRNACDH2 12507 (44%) 2917 (9,2%) 171 (0,5%) 1789 (5,6%) 
 
siRNA-Mediated Knock-Down of N-Cadherin Results in the 
Decrease of AKT Kinase Activity 
Cadherin-directed cell adhesion plays a key role in the 
maintenance
 
of membrane cell signalling, including PI3K/AKT 
[21]. Wnt and AKT are the most important signalling pathways 
involved in cell proliferation (growth). 
AKT kinase is activated by phosphorylation at two sites: T308 
in the kinase domain, and S473 in the regulatory tail. Expression of 
activated AKT was assessed by immunoblotting cell lysates using 
phospho-specific antibodies against phosphorylated S473. To study 
the effect of N-cadherin silencing on the AKT pathway, PI3 kinase 
inhibitor – LY294002 (20μM) was used as a positive control.  
The results indicate that N-cadherin knock-down with CDH2 
leads to a reduced level of S473 phospho AKT leaving total AKT 
expression unchanged (Fig. 2A). Melanoma cells treated with PIK3 
kinase inhibitor –LY294002 showed reduced pAkt level as in case 
of CDH2 siRNA, but did not alter N-cadherin level (Fig. 2A).  
siRNA-Mediated Knock-Down of N-Cadherin Results in the 
Decrease of pERK1/2 Kinase Activity 
The MEK-ERK1/2 signalling pathway is known to regulate 
diverse cellular
 
processes such as proliferation, survival, 
differentiation,
 
motility and invasion [22]. Expression of ERK and 
pERK1/2 was assessed by immunoblotting cell lysates with 
phospho-specific antibodies against phosphorylated T202/Y204. To 
study the effect of N-cadherin silencing on the ERK pathway, 
ERK1/2 kinase inhibitor – U0126 (10μM) was used as positive 
control. 
The decrease of the expression of ERK1/2 in melanoma cell 
lines after knock-down N-cadherin clearly indicates the effect of N-
cadherin on the ERK pathway. There was no change in the 
expression of total ERK (Fig. 2B). The treated melanoma cells with 
ERK1/2 kinase inhibitors – U0126 showed reduced level of 
pERK1/2 as in case of CDH2 siRNA, but did not influence the total 
level of N-cadherin (Fig. 2B).  
N-Cadherin Regulates the Level of -Catenin 
The role of Wnt/-catenin pathway is to regulate cytosolic -
catenin protein level via decomposition of a complex containing 
glycogen synthase kinase-3 (GSK-3), adenomatous polyposis 
coli (APC) and axin. In the absence of Wnt signals, -catenin is 
targeted for ubiquitin-mediated degradation. When released from 
the complex, -catenin translocates to the nucleus and functions as 
a transcription cofactor of the T cell factor (TCF), activating 
responsive genes such as cyclin D1 and c-myc for example [23].  
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-catenin is phosphorylated in its N-terminal domain by GSK-
3, which leads to its degradation by ubiquitination. GSK-3 
constitutively phosphorylates -catenin at S33, S37, and T41 
(S33/37/T41) residues, triggering ubiquitinylation by a Cullin-1-
containing E3 ligase (also known as the SCF complex) before 
proteasomal degradation [24]. 
GSK-3 activity is inhibited by direct phosphorylation at S9. 
On the other hand, GSK-3 also has a tyrosine phosphorylation site, 
and tyrosine phosphorylation of GSK-3 (Y 216) increases its 
activity. siRNA mediated knock-down of N-cadherin resulted in 
inactivation of GSK-3 because phosphorylation of GSK-3 on S9 
was markedly higher, while phosphorylation of GSK-3 (Y 216) 
was markedly lower, compared with the control cells (Fig. 3). N-
cadherin siRNA reduced the total level of -catenin (Fig. 3). There 
was no significant difference between metastatic cell lines: Lu1205, 
WM266-4 and primary (VGP) melanoma cell lines (WM793, 
WM115). The appearance of phosphorylated -catenin at 
(S33/37/T41) was noticed only in the Lu1205 cell line, while the 
decreased phosphorylation of -catenin at S552 and S675 was 
observed after treatment with siRNA against N-cadherin in all 
melanoma cell line (Fig. 3). 
N-Cadherin Regulates Cell Proliferation 
To investigate if and how N-cadherin affects cell proliferation 
in melanoma cells, specific N-cadherin siRNA (siRNACDH2 #1) 
that efficiently reduces N-cadherin expression was used (Fig. 1).  
Cell proliferation was studied with the BrdU ELISA (DNA 
synthesis) and crystal violet (number of cells) tests after 48-72h 
CDH2 siRNA transfection.  
The reduction of cell numbers after 48-72 h knock-down of N-
cadherin
 
compared with control (non-specific siRNA), or non-
treated cells was observed, while no significant
 
differences in 
proliferations were shown after transfection with non-specific 
siRNA (control) or non-transfected cells (data not shown). We did 
not observe cytotoxicity effects after transfection of N-cadherin 
siRNA (LDH activity in media of treated cells ranged from: 0.5-2.7 
%).  
N-cadherin siRNA-transfected cells showed proliferation 
reduced by 50-70% when compared with control cells, regardless of 
the method used (Fig. 4). The effect was observed for metastatic 
cell lines WM793, Lu1205 and WM115 and WM266-4. However, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). The effect of N-cadherin silencing on (A) pAkt and (B) pERK 1/2 expression. Melanoma cells were transfected with non-silencing control siRNA or 
siRNA targeting the N-cadherin 48 h after transfection: protein expression was analyzed by Western blot.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). The effect of N-cadherin silencing on total -catenin and p-GSK expression.  
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the most profound inhibition was noticed in case of WM793 and 
WM266-4, proliferation of which was inhibited after 72h by: 68 % 
(p<0.0001) and 62% (p<0.0001) respectively (Fig. 4). 
N-Cadherin Regulates Cell Cycle 
Contact inhibited cells tend to accumulate at the G1 phase of 
the cell cycle. The relative level of phosphorylated pRb decreases, 
accompanied by accumulation of p27, over expression of wich 
causes cell cycle to arrest in G1. 
N-cadherin and -catenin regulate melanoma cell proliferation 
throughout the inhibition of cell cycle proteins function. Western 
blot analysis showed that levels of cyclin D1 and D3, or cyclin 
dependent kinases CDK4, CDK6 were decreased in N-cadherin 
siRNA treated cells compared to the control. Decreased activity of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). DNA synthesis and proliferation of human melanoma cells.  
Cells were treated for: 48h (A) and 72h (B) with CDH2 siRNA. Assays were performed with conventional methods: BrdU ELISA test for DNA synthesis in 
cells treated for 48h (A) and 72h (B) (Roche according to the manufacturer’s protocol), as well as crystal violet test for proliferation (number of cells) after 72h 
(C) CDH2 siRNA transfection. Cell proliferation is presented as absorbance units (A) at 540nm. 
Values are expressed as mean ±standard deviation in 8 wells in two independent experiments *P<0.05, **P<0.001, ***P<0.00001.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). The effect of N-cadherin silencing on cell cycle protein expression in melanoma cells.  
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cyclin D3 and CDK6 after treatment with PI3K inhibitor LY294002 
was also observed, while ERK1/2 kinase inhibitor - U0126 had no 
affect on the activity of cyclin D3, but led to a decreased level of 
cyclin D1 in WM115 and WM266-4 cell line (Fig. 5). 
Immunoblotting analysis revealed a 2-3-fold increase in the total 
levels of p15, p16, p21, and p27 in N-cadherin silencing cells. A 
similar affect was observed after application of both siRNA: 
CDH2#1 and CDH2#2, with the effect being stronger after using 
CDH2#1. We also noticed increased levels of these proteins after 
application of LY294002 and U1026 inhibitors. This indicated that 
the N-cadherin mediated the entry of melanoma cells into S-phase 
of the cell cycle. In addition, after transfection with N-cadherin 
siRNAs, we observed down-regulation of pAKT and -catenin in 
melanoma cells that caused inhibition of proliferation cells, 
associated with down-regulation of cyclin D1 and D3 proteins, and 
up-regulation of the cell cycle inhibitor p15, p16, p21 and p27.  
DISCUSSION 
The study showed that melanoma cells transfected with N-
cadherin specific siRNA decreased its expression at m-RNA and 
protein level. Transfection of all melanoma cell lines reduced the 
level of N-cadherin successfully and transiently, resulting in 
proliferation inhibition and cell cycle arrest in G1 phase.  
Cancer treatment often involves direct targeting of the enzymes 
essential for growth and proliferation of cancer cells [25]. Dynamic 
regulation of cadherin expression is strongly correlated with 
metastasis and progression of tumours. Many of the changes 
observed involve a key cell
 
cycle step - the entry to S-phase. 
Indeed, this study found most
 
of the cell cycle regulatory proteins, 
including cyclin D1, D3, CDK4, CDK6 and cell cycle inhibitors 
p15, p16, p21 and p27 to be deregulated. 
 Li K et al. (2009) [26] showed that knock-down of N-cadherin 
in ESCC cell line (EC9706) could arrest cell cycle at G0/G1 phase, 
induce cell apoptosis, reduce the invasiveness in vitro, and inhibit 
the tumor formation in vivo.  
According to Smalley (2010) [25], the PI3K/AKT pathway is 
known to regulate proliferation of melanoma cells through the 
regulation of cell cycle entry at G1checkpoint and through the 
inactivation of GSK-3 leading to cyclin D1 deregulation [27]. 
The Wnt/-catenin signalling pathway plays essential role in 
cell proliferation and differentiation, and deregulated -catenin 
protein levels lead to many types of human cancers. 
Stabilized -catenin translocates into the nucleus and 
complexes with members of the T cell factor (TCF)/lymphoid 
enhancer factor (LEF) family of transcription factors [28], leading 
to the activation of Wnt/-catenin responsive genes such as c-myc 
and cyclin D1 [23].  
We observed a decrease in the total level of. -catenin, and its 
decreased phosphorylation at S552 and S675 in all melanoma cell 
lines after their treatment with siRNA against N-cadherin. 
According to Fang 2007 [29], AKT phosphorylates -catenin at 
S552, and phosphorylation of -catenin by AKT translocates -
catenin into the nucleus and increases its transcriptional activity 
promoting tumor cell invasion. AKT-dependent regulation of -
catenin plays a critical role in tumor invasion and development. 
Phosphorylation at S675 also induces -catenin accumulation in the 
nucleus and increases its transcriptional activity [30]. Wnt 
signalling is known to effect cell growth and survival by several 
pathways in part by regulating ERK and PI3K signalling. Notably, 
the PI3K/AKT signalling cascade plays a key role in the control of 
cell proliferation and survival. We and others previously showed 
that PI3K/AKT is an important signalling pathway involved in the 
control of melanoma cell proliferation which, according to present 
results, seems to be significantly controlled by N-cadherin. 
The levels of cyclin D1and D3 or cyclin dependent kinases 
CDK4 and CDK6 were decreased after silencing of N-cadherin 
compared to control. Knock-down of N-cadherin reduced -catenin 
transcriptional activity, which may be responsible for the reduction 
of cyclin D1 and D3 protein level. We have also observed 
decreased activity of cyclin D3 and CDK6 after treatment of cells 
with PI3K inhibitor LY294002, while inhibitor of ERK1/2 kinase - 
U0126 had no effect on the activity of cyclin D3. Application of 
U0126, however, decreased the level of cyclin D1 in WM 115 and 
WM 266-4 cell lines. 
Cell cycle arrest was shown to be accompanied by reduced 
phosphorylation of the retinoblastoma protein Rb as well as reduced 
expression of cyclin D3 and A in cell lines [31]. Cyclin D3 is the 
most widely expressed D type cyclin and its expression can be rate-
limiting for G1/S transition. Levels of cyclin D1 and D3 are 
deregulated in malignant melanoma, cyclin D1 is up-regulated in 
melanoma cells through adhesion independent MEK-ERK1/2 
signalling initiated by mutation of B-Raf [31], but Bhatt et al. 
(2005) [32] suggests that MEK-ERK1/2 signalling controls cyclin 
D1 level in melanoma cells in an adhesion-independent manner. 
Cyclin D3 expression is associated with poor clinical outcome in 
superficial melanoma [33]. According to Spofford 2006 [31], cyclin 
D3 expression was enhanced in a cell panel of human melanoma 
cell lines compared with melanocytes, and was regulated by 
fibronectin-mediated PI3-kinase/AKT signalling, but not MEK-
ERK activity. Some authors have suggested that N-cadherin 
enhances metastasis of breast tumours via increased ERK signalling 
and signal-regulated matrix metalloproteinase (MMP-9) production 
[22]. Our results show that silencing of N-cadherin, followed by 
reduction in pAkt expression, seems to indicate inhibition of cyclin 
D3 expression and involvement in cancer progression. 
 We also observed an increase in expression p15, p16, p21 and 
p27 proteins in cells treated with siRNA for N-cadherin. Increased 
levels of these proteins were also observed after application of 
LY294002 and U1026 inhibitors. 
Studies of familiar malignant melanoma have demonstrated 
mutations in genes regulating G1/S transition including p16 and 
CDK4 [34]. Cyclin D1 is negative in nevi and expressed in 48% 
radial growth phase malignant melanomas [34]. Loss of p27 is 
required for the G1/S transition, as has been demonstrated in 
different experimental models. However over-expression of p27 has 
been found in subset of aggressive diffuse large cell lymphomas 
and Burkitt lymphomas. According to Florenes (2000) [33], vertical 
growth phase malignant melanoma shows simultaneous increase in 
proliferation and decrease in p27 protein
 
expression (p 0.001) 
comparing with radial growth phase or benign
 
lesions. Rössig et al., 
(2001) [35] showed that the AKT down-regulated p27 expression 
by inhibition of Forkhead transcription factor, and, on the other 
hand, stabilized cyclin D protein level via glycogen synthase kinase 
3 inhibition. Regulation of proliferation and cell cycle occurs with 
participation of AKT, and by reducing the level of p21 by 
phosphorylating and inactivating androgen receptor, transcription 
factor for p21 [36]. According to some authors the role of AKT to 
p21 is dependent on dual phosphorylation of p21. p21 
phosphorylation at S146 results in increased p21 stability [37], 
while phosphorylation at T145 blocks nuclear translocation of p21 
with further consequence of cytoplasm location of p21 as 
facilitation of the assembly and activity of the cyclin D-CDK4 
complex, which promotes cell cycle progression through the G and 
into the S-phase [38, 35].  
Our results suggest that knock-down of N-cadherin leads to 
increased level of the cell cycle inhibitors p15, p16, p21 and p27. 
In conclusion, our findings demonstrate that N-cadherin 
regulate melanoma cell proliferation via modulation of AKT, ERK 
and -catenin signalling. Our investigations and literature data 
indicate the oncogenic role of N-cadherin in the activation of AKT, 
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ERK and -catenin pathway. Inhibition of N-cadherin by siRNA 
reduces proliferation through a decrease in the activity of certain 
protein kinases which in turn leads to reduced activity of cyclins 
and increased activity of the cell cycle inhibitors. N-cadherin is 
likely to affect the regulation of proliferation and cell cycle by 
activating the AKT kinase pathway, but details of the mechanism 
are yet to be recognized.  
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